Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Downgrades Zurn Water Solutions to Neutral, Raises Price Target to $38

Baird analyst Mircea Dobre downgrades Zurn Water Solutions (NYSE:ZWS) from Outperform to Neutral and raises the price target from $32 to $38.
byBenzinga Newsdesk
October 15, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Mircea Dobre downgrades Zurn Water Solutions (NYSE:ZWS) from Outperform to Neutral and raises the price target from $32 to $38.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sanofi Announced Pivotal Data Demonstrate Once-weekly Efanesoctocog Alfa Provides Superior Bleed Protection Compared to Prior Factor Prophylaxis

By Charles Gross
July 10, 10:55 AM
Sanofi and Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) presented for the first time today, in a late-breaking session at the 30th International Society on Thrombosis and Haemostasis (ISTH) Congress, positive results from the XTEND-1 pivotal Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001), an investigational factor VIII replacement therap

SNY

Read More

Axcella Announced Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

By Charles Gross
May 26, 7:05 AM
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical tria

AXLA